Fosamax and Osteonecrosis of the Jaw: Causation, Risk, and What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Assessment

Legacy health information resources have long provided the public with structured, accessible data on medical conditions, treatments, and regulatory oversight. These sources, including hospital quality metrics and adverse event databases, serve as foundational tools for understanding general health risks and outcomes. Within this context, the transition from broad health awareness to specific exposure concerns begins with recognizing that certain pharmaceutical interventions carry documented risk profiles that warrant focused examination. The shift from general health science to occupational exposure consideration involves applying the same principles of data-driven inquiry to environments where individuals may encounter heightened risk factors. In mass production settings, workers and nearby populations may face sustained contact with substances or conditions that differ from typical consumer exposure patterns. This pivot requires examining how legacy health data frameworks can be adapted to assess risks in industrial contexts, where exposure duration, concentration, and frequency may amplify potential health consequences. The following discussion narrows this lens to consider a specific pharmaceutical compound and its association with a serious oral condition, drawing on the analytical rigor established in general health information systems while addressing the distinct parameters of occupational exposure.

Fosamax and Osteonecrosis of the Jaw: An Overview of the Evidence

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw. Clinical presentation of ONJ typically involves delayed healing after dental procedures, such as tooth extraction, or local infection, and can occur spontaneously (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is based on clinical examination and imaging, with the condition often associated with invasive dental procedures, cancer diagnosis, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but research suggests that jawbone has unique structural and cellular characteristics that may predispose it to complications from bisphosphonate therapy. A multiscale characterization of jawbone provides information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077). This indicates that the local bone environment in the jaw may be particularly susceptible to the antiresorptive effects of bisphosphonates, potentially impairing bone turnover and healing after minor trauma or infection.

Timeline, Risk Factors, and Causation Considerations

Regarding the timeline between Fosamax exposure and documented harm, the time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuation, but a subset may have recurrence when rechallenged with the same or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A cohort study among female patients treated for osteoporosis in the United Kingdom found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, though absolute risks remained low (approximately 0.05% after 5 years) and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702). Risk considerations for affected patients include the adequacy of warnings. The Fosamax label includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and ONJ onset, as well as the presence of other risk factors such as dental procedures or comorbidities. The evidence indicates that ONJ can occur spontaneously but is generally associated with tooth extraction or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer exposure, and discontinuation of bisphosphonate treatment may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The absolute risk remains low, but the association is supported by epidemiological data showing higher risk with longer treatment duration (https://pubmed.ncbi.nlm.nih.gov/39400702). In summary, Fosamax use is associated with a rare but serious risk of ONJ, with onset varying from days to months after starting therapy. The risk is influenced by duration of use, dental procedures, and other factors. Warnings in the product label address this risk, and discontinuation may reduce harm. Affected patients should consider these factors when evaluating causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with osteonecrosis of the jaw (ONJ), a rare but serious condition where the jawbone fails to heal after minor trauma, such as a tooth extraction. Studies show that the risk increases with longer duration of use, and the condition can occur spontaneously or after dental procedures. The exact mechanism is not fully understood, but it is believed that bisphosphonates suppress bone turnover, particularly in the jawbone. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

How long does it take for Fosamax to cause jaw problems?

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months. Most patients experience relief after discontinuation, but some may have recurrence if rechallenged. The risk is higher with longer treatment duration, with studies showing a threefold increase after 2-3 years and an eightfold increase after 10 years compared to past use. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56, https://pubmed.ncbi.nlm.nih.gov/39400702)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Longer duration of bisphosphonate use also increases risk. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

Does the Fosamax label warn about osteonecrosis of the jaw?

Yes, the Fosamax label includes a warning about ONJ, noting that it has been reported in patients taking bisphosphonates, including Fosamax. The label advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk of ONJ. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.